# Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

> **NCT07333066** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD** · enrollment: 320 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer

## Interventions

- **DRUG:** Apalutamide (Erleada™) 60 mg or 240 mg tablets
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07333066
- **Lead sponsor:** Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333066, "Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*